Business Wire

OR-LATTICE-SEMICONDUCTOR

25.8.2021 22:02:13 CEST | Business Wire | Press release

Share
Lattice Certus-NX FPGAs Optimized for Automotive Applications

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today expanded its growing portfolio of automotive products with the announcement of versions of the Lattice Certus™-NX FPGA family optimized for infotainment, advanced driver assistance systems (ADAS), and safety-focused applications. Built on the Lattice Nexus™ platform, these new Certus-NX devices combine automotive-grade features with best-in-class I/O density, power efficiency, small size, reliability, instant-on performance, and support for fast PCI Express (PCIe) and Gigabit Ethernet interfaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005002/en/

“Demand for automotive semiconductors is increasing as the ongoing trends towards automotive system electrification, autonomy, and connectivity have manufacturers looking for ways to deliver the advanced features and user experiences drivers are looking for in their next vehicle,” said Jay Aggarwal, Director of Silicon Product Marketing, Lattice Semiconductor. “With class-leading performance and power efficiency, support for popular I/O standards in a small form factor, and high reliability, our Certus-NX general purpose FPGAs make a compelling silicon platform for the next-generation automotive applications car makers are eager to provide to their customers.”

“As more automotive systems go digital, modern cars have essentially become mobile datacenters. Automotive developers need access to secure and reliable silicon solutions with fast I/O performance to ensure mission-critical automotive systems can perform their functions instantaneously,” said K. Ganesh Rao, Practice Head – FPGA Solutions, Tata Elxsi. “Lattice Certus-NX FPGAs provide the reliability, performance, and feature set we need to make tomorrow’s automotive applications possible.”

The latest Certus-NX FPGAs are ideal for automotive applications like motor control, LED control in in-vehicle infotainment (IVI) systems, in-vehicle networking (IVN), and sensor data co-processing in ADAS applications. Key features of Certus-NX FPGAs include:

  • Low power consumption – Up to 4X lower power use than similar FPGAs, with a programmable back bias that enables user-selectable high performance or low power operating modes, depending on the needs of the application.
  • Small form factor – Up to 3X smaller with up to 2X the I/O density per mm2 in comparison to similar competing FPGAs.
  • Instant-on performance – Ultra-fast device configuration from SPI memory up to 12X faster than similar competing FPGAs, with individual I/O able to configure in just 3 ms, and full-device startup in only 8-14 ms, depending on device capacity.
  • Robust I/O interfacing capability – Lattice’s extensive Certus-NX I/O IP library includes:
    • 1.5 Gbps differential I/O with performance up to 70 percent higher than competing FPGAs.
    • 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3.
  • Automotive certification and high reliability – Certus-NX FPGAs are AEC-Q100 qualified and provide up to 100X better soft error rate (SER) performance than similar FPGAs.
  • Authentication and encryption – To protect bitstreams against unauthorized access, Certus-NX FPGAs support AES-256 encryption with ECDSA; they are currently the smallest FPGAs on the market to support ECDSA.
  • Ease of use/design – Lattice Radiant® and Lattice Propel™ software tools help simplify and accelerate automotive system design. Certus-NX FPGAs are also supported by the Lattice mVision™ and Lattice sensAI™ solution stacks so designers can leverage the stacks’ modular hardware platforms, reference designs, neural network IP cores, and custom design services to accelerate automotive vision system design.

Automotive-grade versions of Certus-NX FPGAs are now sampling with select customers. For more information about the Lattice technologies mentioned above, please visit:

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo , or Youku .

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye